Data collection for clinical trials ends when the trial closes. However, payer negotiations and post-market regulatory submissions require insights over time horizons typically longer than any single trial provides. Proactively tokenizing clinical trial data allows for not only enrichment during the trial, but also passive long-term follow-up in real-world settings.
Deciding not to tokenize a clinical trial forfeits data you can never recover.
Clinical trial tokenization has moved from an emerging methodology to foundational practice, with tokenized trial volume growing roughly 300% between 2022 and 2024. This Axtria point of view synthesizes the current evidence on benefits, regulatory requirements, technical architecture, therapeutic-area applications, and HEOR value. It makes the case for embedding tokenization by default from Phase II onward, and shows what sponsors lose when they treat it as optional.
What the evidence shows across regulatory strategy, HEOR, and real-world data linkage
- Tokenization enables passive, low-cost follow-up of trial participants through linked real-world data for up to 15 years after a study closes, with no return site visits required.
- Consent and PII collection must be embedded at protocol design; retrofitting tokenization after enrollment closes is operationally difficult and frequently impractical.
- In HEOR, tokenization replaces modeled assumptions with real patient-level data: claims-based resource use, true adherence rates, and registry-linked survival, making cost-effectiveness models far more defensible to HTA reviewers.
- Oncology, rare disease, and general medicine each gain distinct value, from long-term survival follow-up to passive data collection in small populations to post-market safety surveillance.
This point of view is written for the teams making tokenization decisions now.
It was authored by Axtria's AI & Data practice and draws on peer-reviewed research and industry analyses published between 2023 and 2026, including FDA guidance, GDPR frameworks, and published HTA reassessment studies. Download the POV to see the complete analysis of tokenization benefits, regulatory requirements, technical architecture, and the six strategic recommendations for sponsors.
Contact our Clinical Solutions team today to see how we can build tokenization-ready clinical trials.
FAQs
